about
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypesSorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy.A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breastPIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ...Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
P50
Q27851705-C4E3BF64-A5B6-43D5-B15A-1D95F88AB63FQ30758991-6BE775FD-40C8-4BC0-AE6F-9219589FCBFEQ30976616-B938CB95-2AB5-4488-AF13-F6F42C5463CCQ33406730-F8ECBE1B-BF6D-4704-9C84-32E75DC9046FQ33415041-4C20981D-A94B-471D-9C50-EFBF6AFDCBEEQ33515646-16FAD1C2-0635-4335-80D7-9CC8B6874895Q34006749-731FF4D7-C8E1-4C36-B792-611E3837148FQ34042709-F609D1B9-411D-40B5-9B7E-B58D321A0BE4Q34583705-7ECEFA9C-CB96-4919-8154-65A9AAC891DDQ35576256-F641817F-4F90-4AFD-9520-CC65CA0C3CC2Q35674616-85F471A4-D455-4B65-9759-47E9EAF823AAQ36678684-8CE1AA9D-7803-43C5-95F6-4ED57292CC51Q37380424-E95BBE86-BB32-4B44-9983-28686A4276AEQ37738972-141CFB2D-8D91-4BC6-9E7A-4AC345D94274Q38188183-F9A9A27E-DC76-4086-9603-7993690B5492
P50
description
onderzoeker
@nl
name
Holger Eidtmann
@ast
Holger Eidtmann
@en
Holger Eidtmann
@es
Holger Eidtmann
@sl
type
label
Holger Eidtmann
@ast
Holger Eidtmann
@en
Holger Eidtmann
@es
Holger Eidtmann
@sl
prefLabel
Holger Eidtmann
@ast
Holger Eidtmann
@en
Holger Eidtmann
@es
Holger Eidtmann
@sl